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Abstract
Losartan and honokiol are small molecules which have been described to inhibit aggregation of
platelets by collagen. Losartan has been proposed to block clustering of GPVI but not to affect
binding of collagen. Honokiol has been reported to bind directly to GPVI but only at
a concentration that is three orders of magnitude higher than that needed for inhibition of
aggregation. The mechanism of action of both inhibitors is so far unclear. In the present study,
we confirm the inhibitory effects of both agents on platelet aggregation by collagen and show that
both also block the aggregation induced by the activation of CLEC-2 or the low affinity immune
receptor FcγRIIa at similar concentrations. For GPVI and CLEC-2, this inhibition is associated with
a reduction in protein tyrosine phosphorylation of multiple proteins including Syk. In contrast, on
a collagen surface, spreading of platelets and clustering of GPVI (measured by single molecule
localisation microscopy) was not altered by losartan or honokiol. Furthermore, in flow whole-
blood, both inhibitors suppressed the formation of multi-layered platelet thrombi at arteriolar
shear rates at concentrations that hardly affect collagen-induced platelet aggregation in platelet
rich plasma. Together, these results demonstrate that losartan and honokiol have multiple effects
on platelets which should be considered in the use of these compounds as anti-platelet agents.
Keywords
CLEC-2, GPVI, GPVI, honokiol, losartan,
platelets
History
Received 3 October 2018
Revised 10 February 2019
Accepted 17 February 2019
Introduction
Haemostasis is a finely regulated process triggered after vessel wall
injury serving to curtail blood loss and to restore vascular integrity.
One of the key components of haemostasis are platelets, which rapidly
adhere and aggregate at sites of a lesion [1]. Glycoprotein VI (GPVI),
a member of the immunoglobulin superfamily, is the major signalling
receptor for collagen and fibrin [2–5]. GPVI is expressed on the sur-
face membrane in complex with the FcRγ chain which contains an
immunoreceptor tyrosine activation motif (ITAM) characterized by
two YxxL/I sequences (where x is any amino acid) separated by 12
amino acids. Src kinases associated with the cytoplasmic tail of GPVI
initiate phosphorylation of two conserved tyrosines in the ITAMof the
FcRγ chain [6,7]. This leads to the recruitment and activation of Syk
via its SH2 domains, and triggering of a phosphorylation complex
consisting of adapter and signalling proteins that culminates in Ca2+
mobilisation and platelet activation [8,9].
The C-type lectin-like receptor, CLEC-2, has a single copy of
a YxxL sequence known as a hemITAM. Phosphorylation of two
CLEC-2 receptors leads to binding of Syk and initiation of
a signalling cascade that is similar to that driven by the GPVI-
FcRγ–chain [10–12]. To date, podoplanin is the only established
endogenous ligand for CLEC-2. Podoplanin is expressed on the
surface of a variety of cells including epithelial and stromal cells
but is absent from vascular endothelial cells. Although its func-
tion in haemostasis is not clear, there is evidence that CLEC-2
play a pivotal role in arterial and venous thrombosis [13,14].
Losartan, an angiotensin II receptor antagonist, has been proposed
to inhibit clustering but not binding of GPVI to collagen [15,16],
leading to inhibition of platelet activation in vitro and reduced platelet
accumulation after carotid injury in mice [17–20]. Honokiol is
a natural bioactive molecule isolated from Magnolia species, which
is used in traditional Chinese medicine. Honokiol is a multifunctional
compound with many potential therapeutic properties, including anti-
oxidant, anti-inflammatory, anti-cancer, anti-depressant and anti-
neurodegeneration activities [21–23]. Honokiol also has anti-
thrombotic effect, and has been shown to bind to GPVI at concentra-
tions that are three orders of magnitude higher than those required for
inhibition of platelet aggregation, suggesting an alternative mechan-
ism of inhibition [24,25].In the present study, we have further inter-
rogated the mechanism of action for both inhibitors.
Material and Methods
Reagents
Horm collagen and collagen diluent were purchased from Nycomed
(Munich, Germany). CRP (ten glycine-proline-hydroxproline [GPO]
Color versions of one or more of the figures in the article can be found
online at www.tandfonline.com/iplt.
Correspondence: Steve P. Watson, Institute of Cardiovascular Sciences,
IBR Building, College of Medical and Dental Sciences, University of
Birmingham, Birmingham B15 2TT, UK. E-mail: s.p.watson@bham.ac.uk
This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0/),
which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly cited.
http://www.tandfonline.com/iplt
ISSN: 0953-7104 (print), 1369-1635 (electronic)
Platelets, Early Online: 1–11
© 2019 Taylor & Francis Group, LLC. DOI: https://doi.org/10.1080/09537104.2019.1585526
repeats) was crosslinked as described [26]. Rhodocytin was purified
in the Eble lab (University of Münster, Germany) from the crude
venom of Calloselasma rhodostoma. The mouse monoclonal anti-
bodies (mAbs) anti-phosphotyrosine clone 4G10 (05–321) and rab-
bit polyclonal anti-FcR γ-chain (06–727) were purchased from
Merck Millipore (Watford, UK). The rabbit polyclonal antibody
anti-Syk (sc-1077), the mouse mAbs anti-Syk 4D10 (sc-1240) and
anti-FcR γ-chain (sc-390222) were purchased from Santa Cruz
(Wembley, UK). All other reagents including losartan, honokiol
and the anti-mouse IgG (Fc specific) F(ab′)2 fragment antibody
were purchased from Sigma-Aldrich (Poole, UK), or came from
described sources [3]. Losartan was dissolved in water and honokiol
in DMSO. The mouse monoclonal mAb IV.3 against the low affinity
immune receptor FcγRIIA was purified from the hybridoma
obtained from the American Type Culture Collection. 1G5-Fab
against Pan-GPVI was gift from Elizabeth Gardiner (Australian
National University, Canberra, Australia).
Platelet Isolation
Venous blood was taken from healthy volunteer using 3.8% (v/v)
sodium citrate (1:9) as the anti-coagulant with informed consent
according to the guidelines of the local ethics committee
(ERN_11-0175). All steps of this study complied with the ethical
principles according to the Declaration of Helsinki. Acid Citrate
Dextrose (ACD, 1:10) was added to the blood. Platelet-rich
plasma (PRP) was obtained by centrifugation at 200 g for
20 min at room temperature. Washed platelets were obtained by
centrifugation at 1000 g for 10 min at room temperature using
prostacyclin (2.8 μM) and resuspended in modified
Tyrode’s-HEPES buffer (134 mMNaCl, 0.34 mM Na2HPO4,
2.9 mMKCl, 12 mM NaHCO3, 20 mM HEPES, 5 mM glucose,
1 mM MgCl2; pH7.3) Washed platelets were used at 2 × 10
7/ml
for static adhesion or 5 × 108/ml for other studies.
Platelet Aggregation
Washed platelets at 5 × 108/ml were pre-treated for 5 min with
different concentrations of losartan, honokiol or solvent controls
prior to stimulation by collagen, rhodocytin, thrombin or mAb IV.3
crosslinked with F(ab’)2. Light transmission was recorded at 37°C
with stirring (1200 rpm) in an aggregometer (Chrono-Log Stago,
Havertown, Pennsylvania, USA). ATP secretion was monitored in
washed platelets in parallel with platelet aggregation by adding
firefly luciferase and luciferin (2 μM) and comparing the lumines-
cence generated by platelet ATP release with an ATP standard.
Platelet Spreading
Glass coverslips were coated in the presence of 10 μg/ml of
collagen or fibrin generated as described previously [5].
Following washing with PBS, the coverslips were blocked with
5 mg/ml heat-inactivated bovine serum albumin (BSA) in PBS for
60 min. Washed platelets 2 × 107/ml were incubated with hono-
kiol (25 µM), losartan (25 µM) or solvent controls prior to be
allowed to spread for 30 or 45 min, for human or mouse platelets
respectively, at 37°C . The cells were then washed with PBS
followed by fixation with paraformaldehyde (3.7%) for 10 min.
For actin staining, the platelets were permeabilised with 0.1%
Triton X-100 for 5 min and stained with Alexa-488-labelled
phalloidin for 45 min in the dark. Platelets were imaged on
a Zeiss Axiovert 200 M microscope. Fluorescence from platelets
was analysed using ImageJ (NIH, Bethesda, USA). In each inde-
pendent experiment, 5 random fields of view per condition were
analysed, with at least 100 platelets in total per condition.
Protein Phosphorylation Study
In presence of eptifibatide (9 µM), washed platelets 5 × 108/ml
were pre-treated for 5 min with honokiol (25 µM), losartan (25 µM)
or solvent controls prior to activation by collagen (3 µg/ml), rho-
docytin (150 µM) or thrombin (1 U/ml) with or without fibrinogen
(200 µg/ml) at 37°C with stirring (1200 rpm) in an aggregometer
for 60 seconds. Activation was terminated with 2x ice-cold lysis
buffer (300 mM NaCl, 20 mM Tris, 2 mM EGTA, 2 mM EDTA,
and 2% IGEPAL CA630 [NP-40 equivalent], pH 7.4, plus 2. mM
Na3VO4, 100 mg/mL AEBSF [4-{2-aminoethyl} benzenesulfonyl
fluoride hydrochloride], 5 mg/mL leupeptin, 5 mg/mL aprotinin,
and 0.5 mg/mL pepstatin). Whole cell lysates (WCLs) were pre-
pared by boiling a sample of lysate with sodium dodecyl sulfate
(SDS) sample buffer. Syk was immunoprecipitated with 2 µg of
Syk antibody (4D10) and incubated protein A-Sepharose beads
overnight at 4°C. The beads were then washed, and proteins were
eluted by boiling in SDS sample buffer. Immunoprecipitates (IPs)
and WCLs were separated by SDS-polyacrylamide gel electrophor-
esis, electrotransferred, and western blotted. All primary antibodies
were used diluted at 1/1000 in TBS-Tween-BSA 5% for overnight
at 4°C. The secondary antibodies were used diluted at 1/10000 in
TBS-Tween for 1 h at room temperature. Western blots were
imaged with autoradiographic film.
Cell/NFAT Assay
The following constructs and plasmids were used for GPVI trans-
fections into cells for NFAT-luciferase assays as previously
described [27]. Human GPVI sub-cloned into pcDNA3 with
a C-terminal Myc tag and human FcRγ (untagged) in pEF6
were generated. The nuclear factor of activated T cells (NFAT)-
luciferase reporter containing three copies of the distal NFAT site
from the IL-2 promoter as described previously [28]. In brief,
indicated amounts of DNA of each construct and 15 μg of NFAT-
luciferase reporter construct were transfected by electroporation at
350 V and 500 µF microfarads into 2 × 107 DT40 cells. The
transfected cells were incubated with losartan at 25 µM or
250 µM and stimulated by collagen at 10 µg/ml for 6 h at 37°C.
Luciferase activity was measured with a Centro LB960 micro-
plate luminometer (Berthold Technologies, Germany).
Platelet Spreading and Staining for STORM Imaging
For STORM imaging, 35 mm #1.5 (0.17 mm) glass bottomed
MatTek dishes (MatTek Corporation, USA) were coated with
10 μg/ml Horm collagen diluted in manufacturer-supplied diluent
or in 10 μg/ml cross-linked collagen related peptide (CRP-XL) using
phosphate-buffered saline (PBS) and stored overnight at 4°C. Dishes
were blocked with 5 mg/ml BSA for 1 h at room temperature then
washed with PBS. Washed and rested human platelets, diluted to
2 × 107/ml in modified Tyrode’s buffer were incubated with 2 μg/ml
1G5-Fab against Pan-GPVI for 5 min at 37°C. The labelled platelets
were then incubated with 25 μM losartan or 25 μM honokiol or
vehicle (PBS for losartan or DMSO for honokiol) for another 5 min
at 37°C before being transfered onto the coated MatTek dishes.
Platelets were allowed to spread for 45 min at 37 °C and rinsed
once wit PBS to remove unbound platelets. Adhered platelets were
fixed for 10minwith 10% neutral buffered formalin solution (Sigma,
Poole, UK), followed by 5 min permeabilisation with 0.1% Triton
X-100 in PBS. After PBS washes, the platelets were blocked for
1 hour at room temperaturewith 1%BSA+ 2% goat serum (in PBS).
1G5-Fab-labelled platelets were secondary labelled with anti-
mouse-Alexa647 antibody and stained for actin with Alexa488-
phalloidin (both from ThermoFisherScientific; 1:300 diluition in
block buffer) for 1 h at room temperature. Platelet samples were
washed at least three times with PBS prior to imaging.
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STORM Imaging
Single-molecule images of platelet GPVI were acquired using
a 100 × 1.49 N.A. TIRF objective lens on a Nikon N-STORM system
in TIRF and dSTORM mode. The sytem was equipped with a Ti-E
stand with Perfect Focus, Agilent Ultra High Power Dual Output
Laser bed (containing a 170-mW 647-nm laser and a 20-mW 405
laser) and an Andor IXON Ultra 897 EMCCD camera. Fluorophore
blinking was achieved by imaging the samples in a PBS based buffer
containing 100mMMEA-HCl, 50 µg/ml glucose oxidase and 1 µg/ml
catalase as detailed in Metcalf et al [29]. Single colour (Alexa647)
imaging was performed using the N-STORM emission cube with
reactivation of fluorophore blinking achieved by increasing the
405 nm laser power by 5% every 30 sec. For each image, 20,000
frames were acquired using the Nikon NIS Elements v4.5 software
with an exposure time of 9.2 ms, gain 300 and conversion gain 3.
C
Lo
Lo
Lo
0
20
40
60
80
0 1 5 10 25 µM losartan
)
%(
n
oita
ger
g
g
A
Collagen (1µg/ml)
0
20
40
60
80
***
***
***
)
%(
n
oita
ger
g
g
A
0 1 5 10 25 µM losartan
0
2 0
4 0
6 0
8
0
20
40
60
80
A
g
g
re
g
at
io
n
 (
%
)
0 1 5 10 25 µM honokiol
Collagen (1µg/ml)
Collagen (1µg/ml)
0
2 0
4 0
6 0
8 0
* * *
* * *
* * *
0 1 5 10 25 µM honokiol
A
g
g
re
g
at
io
n
 (
%
)
Collagen (1µg/ml)
2
4
6
8
1 0 0
C
Lo
Lo
0
20
40
60
80
0 1 5 10 25 µM losartan
)
%(
n
oita
ger
g
g
A
Rhodocytin (150nM)
8 0
1 0 0
* * *
* *
)
%(
n
oita
ger
g
g
A
0 1 5 10 25 µM losartan
0
20
40
60
Rhodocytin (150nM)
80
10
0
2 0
4 0
6 0
8 0
1 0 0
* * *
* * *
* * *
A
g
g
re
g
at
io
n
 (
%
)
0 1 5 10 25 µM honokiol
0
20
40
60
80
Rhodocytin (150nM)
100
0
2 0
4 0
6 0
8 0
0 1 5 10 25 µM honokiol
0
20
40
60
80
A
g
g
re
g
at
io
n
 (
%
)
Rhodocytin (150nM)
A
B
Figure 1. Losartan and honokiol dose-dependently reduce aggregation of washed platelets induced by collagen or rhodocytin. Washed platelets were
pretreated with different concentrations of losartan or honokiol for 3 min before stimulation with a. collagen 1µg/ml or b. rhodocytin 150 nM. Bar
graphs represent results from a total of 5 independent experiments and results are shown as mean ± SD **P < .01, ***P < .001.
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Image reconstruction to obtain localisation co-ordinates for each
identified fluorescence blink was undertaken with the Nikon
STORM analysis module 3.2 using drift correction and Gaussian
rendering. For each condition, 5 different fields of view (FOV) from
3 independent experiments were captured. Only data points with
a photon count>500 were included in the cluster analysis.
For the analysis of dSTORM data, localised data points within
each FOV were grouped into clusters using density-based clustering
of applications with noise (DBSCAN). The clustering was executed
using the open-source software KNIME and the R package ‘dbscan’
(workflow available on request) [30]. The radius of local neighbour-
hood was set to 40 nm and 50 nm, and the minimum number of
directly reachable points was set to 15 and 10, for CRP and collagen
respectively. Cluster areawas calculated by placing a circle of radius
30 nm over every detection in a cluster and calculating the union of
these circles. This was estimated using a grid with pixel size 5 nm
and image based dilation. The analysis was performed on whole
FOVs and the quantitative cluster data was outputted as
a spreadsheet. Graphs and statistics of the clustering data were
calculated in Graphpad Prism 7.
Whole Blood Thrombus Formation
Whole blood thrombus formation was assessed under flow con-
ditions as described elsewhere [31]. In brief, glass coverslips were
coated with 2 µl of 50 µg/ml collagen type I and mounted onto
a transparent parallel-plate flow chamber. Blood samples treated
with honokiol or losartan or vehicle were re-calcified with
3.75 mM MgCl2 and 7.5 mM CaCl2 in the presence of 40 µM
active-site thrombin inhibitor PPACK, prior to experimentation.
Recalcified blood samples were perfused for 6 min at wall shear
rate of 1000 s−1 over the microspot surface. Representative phase-
contrast microscopic images were captured using a fast line-
scanning Zeiss LSM7 microscope equipped with 63x oil-
immersion objective. Images were analysed using Fiji software
[32]. Four outcome parameters were assessed: platelet surface
A
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Figure 2. Losartan and honokiol inhibit platelet protein tyrosine phosphorylation, including Syk, induced by collagen or rhodocytin. Washed platelets
were pre-treated with 25 µM of losartan or honokiol for 3 min before stimulation with collagen 3 µg/ml or rhodocytin 150 nM. Stimulations were
stopped with addition of lysis buffer. a. whole-cell lysate (WCL) and b. immunoprecipitate (IP) of Syk. WCL and IP were separated by SDS-
polyacrylamide gel electrophoresis and Western blotted for pTyr and Syk, respectively. The first lane shows the molecular weight markers (MW).The
results are representative of 3 independent experiments.
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area coverage, thrombus morphological score (0–5), thrombus
contraction score (0–3) and platelet multilayer score (0–3) as
previously explained [31,33]. Scoring was done by visual inspec-
tion of brightfield images based on a pre-defined score system.
Morphological score indicates the aggregate formation by using
a 5-point scale: 0: no platelet adhesion; 1: single platelet (>15)
adhesion, 2: platelet monolayer; 3: small aggregates; 4: medium
size aggregates; 5: large aggregates respectively. Thrombus con-
tractility is appreciated based on a 3-point scale, where 0: no
aggregate formation, 1: loose aggregates; 2: aggregates started to
contract; 3: tightly packed, dense aggregates respectively.
Multilayer score refers to thrombus volume on a 3-point scale,
where 0: monolayer of platelets; 1: 2 layers of platelets; 2: multi-
ple layer of platelets; 3: large, really high thrombi respectively.
Data Analysis
Statistical analysis was realised by ANOVAwith Turkey post-test.
A P value of <0.05 was considered to be significant.
Results
Comparison of Losartan and Honokiol in Platelet
Aggregation
In a previous study, platelet aggregation induced by 10 µg/ml
of collagen was found to be inhibited by losartan with an IC50
of 6.3 µM [21] and by honokiol with an IC50 of 0.6 µM [26].
In Figure 1, we demonstrate, by comparing the two com-
pounds, that losartan and honokiol dose-dependently inhibited
aggregation of washed platelets induced by 1 µg/ml collagen
with an IC50 of 3.7 µM for losartan and of 4.6 µM for
honokiol. At these concentrations, neither inhibitor had an
effect on platelet activation by thrombin or the thromboxane
mimetic U46619 (data not shown). On the other hand, both
losartan and honokiol delayed and reduced aggregation to the
CLEC-2 agonist rhodocytin with IC50 values of 3.5 µM and
2.1 µM, respectively (Figure 1) and furthermore inhibited the
platelet response to the low affinity immune receptor FcγRIIA
over the same concentration range (Supplemental Figure 1).
Collagen and rhodocytin induce a similar pattern of increase
in tyrosine phosphorylation, which was abrogated by losartan
or honokiol at approximately 10x their IC50 values (Figure 2).
In addition, both inhibitors blocked tyrosine phosphorylation of
the tyrosine kinase Syk (Figure 2).
Losartan and Honokiol were less potent in the presence of
plasma, due to protein binding, requiring a concentration of
250 µM to achieve inhibition of aggregation (Supplemental
Figure 2) [32]. At this concentration, losartan inhibited NFAT
activation by GPVI and CLEC-2 in a transfected cell line model
in the presence of serum (Figure 3a), but did not have an effect on
constitutive signalling (i.e. ligand independentl signalling) of
either receptor (Figure 3b). Honokiol could not be tested in the
cell line model due to the effects of vehicle DMSO on NFAT
activity.
Losartan and Honokiol Do Not Block Platelet Spreading or
Ligand Binding to GPVI
Losartan and honokiol (both used at 25 µM in Tyrode’s buffer)
did not have significant effects on the adhesion or spreading of
platelets on collagen (Figure 4). Similar results were observed
at 100 µM (data not shown). Further, neither compound altered
clustering of GPVI by CRP (Figure 5) or by collagen (not
shown) as measured by single molecule localisation micro-
scopy (dSTORM). This result is consistent with the lack of
interference of either compound with GPVI-collagen binding,
in an ELISA competitive binding assay using recombinant
GPVI (Supplemental Figure 3) [21].
Figure 3. Losartan reduces signalling induced
by collagen in transfected DT40 cells. DT40
B-cells were transfected with a NFAT-luciferase
reporter construct, a β-galactosidase construct to
control for transfection efficiency, and two
GPVI and FcRγ-chain(Fcγ) expression con-
structs or empty control (CTL) vectors. Sixteen
hours post-transfection, expression of GPVI was
confirmed by flow cytometry (data not shown).
The transfected cells were pre-treated with
losartan (LOS) at 25 μM or 250 μM. They were
either a. stimulated with collagen (10 μg/mL) or
PMA (50 ng/mL) plus ionomycin (1 μM) or
b. unstimulated. Six hours later, cells were lysed
and assayed for luciferase and β-galactosidase.
Luciferase data were normalized for β-
galactosidase expression. Error bars represent
the SEM from three independent experiments. *
P < .001
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Losartan and Honokiol Inhibit Thrombus Formation
Whole blood perfusion experiments were performed on col-
lagen-coated microspots to assess the effects of platelet pre-
treatment with losartan or honokiol (25–100 µM). Thrombi
were analysed for platelet deposition (% surface area cover-
age) and by visual inspection using a pre-defined score sys-
tem (morphological, contraction and multilayer score)
[33]. Losartan treatment did not affect platelet deposition
(Figure 6a,b) but decreased thrombus contraction and
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Figure 4. Losartan and honokiol do not affect platelet spreading on collagen. Glass coverslips were coated with collagen.Washed platelets were pre-
treated with 25 µM of a. losartan or b. honokiol before spreading on collagen, followed by fixation and staining for actin with Alexa-488 phalloidin.
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multilayer scores (Figure 6d,e) as an indication of lower
thrombus integrity and the prpesence of loose platelet aggre-
gates. In contrast, honokiol pre-treatment resulted in a dose-
dependent decrease in platelet adhesion (lower surface area
coverage of platelets) to collagen and significantly decreases
the contraction and multilayer scores (Figure 7), pointing to
a suppressed formation of tightly packed thrombi. These
results show that both losartan and honokiol affect formation
of thrombi in whole blood but in different ways. These
concentrations of the two inhibitors have little effect however
on the response to GPVI activation of platelets in platelet
rich plasma due to protein binding (see above).
Discussion
This work provides new information on the platelet inhibition
mechanisms of losartan and honokiol. We confirmed that losartan
and honokiol inhibit platelet aggregation by collagen. However,
while the IC50 for losartan was similar to that previously reported
[21], the IC50 for honokiol is almost one order of magnitude higher
than in the original report [26]. The explanation for this difference is
unclear. Interestingly, both losartan and honokiol inhibited platelet
activation by the (hem)ITAM receptors rhodocytin and FcγRIIA at
similar concentrations to those for inhibition by collagen. This effect
was mediated by inhibition of tyrosine phosphorylation, including
Figure 5. Losartan and honokiol do not affect clustering of GPVI. Glass coverslips were coated with CRP. Washed platelets were pre-incubated with
1G5 Fab (pan-GPVI), then pre-treated with 25 µM losartan, 25 µM honokiol or vehicle before spreading on CRP. Following fixation, GPVI was
secondary labelled with mouse-Alexa647 and actin was labelled with Alexa488-phalloidin. The single molecule localisation data acquired by STORM
was analysed for clustering using DBSCAN. Different colours represent different clusters (with black dots representing noise).For each condition, 5
different fields of view (FOV) from 3 independent experiments were captured. Representative cropped scatter plots for each condition show the output
of the DBSCAN clustering algorithm (left panel). Scale bars: 1 µm and 0.1 µm. Bar graphs show quantification of cluster density, cluster area and
number of detections per cluster. Mean ± SEM (n = 3) (right panel).
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Syk which plays a proximal role in signalling by all three receptors.
Inhibition of the response to GPVI was not due to a direct competi-
tion with collagen since losartan did not block binding of recombi-
nant GPVI to collagen [15] and honokiol inhibited this binding at
a concentration that is three orders of magnitude greater than
required for inhibition of aggregation [25].
Although both losartan and honokiol inhibited platelet aggre-
gation and Syk phosphorylation, they were unable to prevent
clustering of GPVI or spreading on collagen at concentrations
up to 100 µM. This may be related to the relatively high concen-
tration of collagen on the surface thus overcoming the inhibitory
effect of the two reagents. Alternatively, neither agent may be
able to inhibit clustering of GPVI on a surface and therefore
inhibit activation, in contrast to previous results in suspension
using an antibody that recognises the dimeric form of GPVI
(9E18) conjugated with Duolink PLA probes [15]. Losartan had
Figure 6. Losartan inhibits the formation of contracted, multilayered platelet thrombi under flow. Whole blood treated with vehicle solution or losartan
was perfused over collagen surface for 6 min at wall shear rate of 1000 s−1. Phase contrast images were captured and shown as representative images
a. Platelet surface area coverage (% SAC), thrombus morphological score (range 0–5), thrombus contraction score (0–3) and platelet multilayer score
(0–3) were determined b-e. Data are presented as mean ± SEM (n = 4). *P < .05, **P < .01, ***P < .001.
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no effect on constitutive signalling by GPVI in transfected DT40
cells, which may be a functional readout for clustering of the
immunoglobulin receptor.
Losartan and honokiol are highly protein bound in plasma
[18,32,34] necessitating use of higher concentrations in the pre-
sence of plasma to achieve the same level of inhibition as seen in
washed platelets. Unexpectedly however, both inhibitors sup-
pressed collagen-dependent platelet aggregation in whole blood
under flow conditions at concentrations that hardly affect platelet
aggregation in plasma as measured by light transmission aggre-
gometry. Furthermore, the mode of inhibition under flow was
distinct for the two inhibitors: while both suppressed the forma-
tion of tight platelet thrombi, honokiol also interfered with plate-
let adhesion. One explanation for the inhibition observed in whole
blood could be based on their lipophilic characteristic causing
disruption of lipid-to-lipid or lipid-protein interactions [35,36] or
blocking protein-protein interactions. In addition, honokiol has
been reported to disrupt the integrity of the inner membrane of
Figure 7. Honokiol inhibits both platelet adhesion and formation of multilayered platelet thrombi under flow. Whole blood treated with vehicle solution
or honokiol was perfused over collagen type I for 6 minutes at wall shear rate of 1000 s−1. Phase contrast images were captured and shown as
representative images a. Platelet surface area coverage (% SAC), thrombus morphological score (range 0–5), thrombus contraction score (0–3) and
platelet multilayer score (0–3) were determined b-e. Data are presented as mean ± SEM (n = 4). *P < .05, **P < .01, ***P < .001.
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mitochondria [37]. These data could explain the pleiotropic
impacts on various cells in different pathologies [38].
In this study, we compared two small molecules described as
specific inhibitors for GPVI on different aspects of platelets
activation and function. Although both compounds were able to
inhibit platelet aggregation induced by collagen, we could not
confirm the original potency of honokiol on this response and we
found that neither agent inhibited spreading of platelets on col-
lagen. The likely explanation is that both comounds are unable to
inhibit clustering of GPVI of platelets on a surface. Both inhibi-
tors also blocked rhodocytin and FcγRIIA-induced CLEC-2 acti-
vation demonstrating that they are not specific to GPVI at the
concentrations used. This is illustrated by the inhibition of platelet
aggregation on whole blood under flow conditions at concentra-
tions that have a minimal effect on platelet activation by collagen
in plasma. The multiplicity of effects of the two inhibitors should
be considered in the context of their use as anti-platelet agents.
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